Roth Capital Partners upgraded Cempra (NASDAQ:CEMP) to “buy” and maintained its $8 price target after the company announced positive Phase 3 results in the first of two skin infection (ABSSSI) studies with Taksta. The stock was quoted at $4.20 near midday on Feb. 27.Read More
H.C. Wainwright launched coverage of Cidara Therapeutics (NASDAQ:CDTX) with a “buy” rating and $25 price target. The stock closed at $10.80 on Dec. 16.Read More
Dipexium Pharmaceuticals (NASDAQ:DPRX) has completed the patient enrollment objective in the OneStep-2 Phase 3 clinical trial of its Locilex topical antibiotic peptide.
The company’s OneStep-1 Phase 3 clinical trial has passed the 98% enrollment mark and is expected to reach the 180-patient enrollment objective soon.Read More
H.C. Wainwright has initiated coverage of Paratek Pharmaceuticals (NASDAQ:PRTK) with a “buy” rating and $32 price target. The stock closed at $15.51 on Friday.
Paratek’s lead drug, omadacycline, is a broad-spectrum antibiotic with potent coverage of common bacterial pathogens such as MRSA in both acute bacterial skin and skin structure infection (ABSSSI) and community-acquired bacterial pneumonia (CABP); multi-drug resistant Streptococcus pneumoniae (MDRSP) in CABP; and extended spectrum beta-lactamase-producing Enterobacteriaceae in urinary tract infections (UTI).Read More